These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19731514)

  • 1. Prasugrel, new platelet inhibitor, subject of formulary debates.
    Morrow T
    Manag Care; 2009 Aug; 18(8):56-7. PubMed ID: 19731514
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
    Gurbel PA; Tantry US
    Curr Opin Investig Drugs; 2008 Mar; 9(3):324-36. PubMed ID: 18311669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of prasugrel, a novel thienopyridine.
    Angiolillo DJ; Bates ER; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S16-22. PubMed ID: 18657682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel, a new platelet inhibitor.
    Yee D; Meyer J; Caliendo G; Oviedo V
    Mt Sinai J Med; 2010; 77(3):315-23. PubMed ID: 20506458
    [No Abstract]   [Full Text] [Related]  

  • 5. Mortality in the TRITON trial: update from the FDA prasugrel action package.
    Wiviott SD; Antman EM; Braunwald E
    Am J Cardiol; 2010 Jul; 106(2):293-4. PubMed ID: 20599020
    [No Abstract]   [Full Text] [Related]  

  • 6. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W; Gurvitch R; Ajani AE
    Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial.
    Capodanno D; Tamburino C
    Int J Cardiol; 2011 Jan; 146(2):242-3. PubMed ID: 21130510
    [No Abstract]   [Full Text] [Related]  

  • 9. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
    MMW Fortschr Med; 2009 Sep; 151(36):50. PubMed ID: 19813542
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel.
    Fuster V; Farkouh ME
    Circulation; 2008 Oct; 118(16):1607-8. PubMed ID: 18852375
    [No Abstract]   [Full Text] [Related]  

  • 12. Smoking and prasugrel.
    Ye Y; Xie H; Zhao X; Zhang S
    Int J Cardiol; 2013 Sep; 168(2):1590-1. PubMed ID: 23395458
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA prasugrel review: adjudication of myocardial infarction controversy.
    Serebruany VL
    Cardiology; 2009; 114(2):126-9. PubMed ID: 19506374
    [No Abstract]   [Full Text] [Related]  

  • 15. Prasugrel as a potential cancer promoter: review of the unpublished data.
    Floyd JS; Serebruany VL
    Arch Intern Med; 2010 Jun; 170(12):1078-80. PubMed ID: 20585076
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecule of the month. Pasugrel.
    Drug News Perspect; 2006 Oct; 19(8):490. PubMed ID: 17160150
    [No Abstract]   [Full Text] [Related]  

  • 17. [American Heart Association conference 2008. The JUPITER trial, the approval of prasugrel, the (aging) heart of obese adolescents].
    Schaerlig E
    Rev Med Suisse; 2009 Feb; 5(192):482-5. PubMed ID: 19317316
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.
    Passaro D; Fadda V; Maratea D; Messori A
    Int J Cardiol; 2011 Aug; 150(3):364-7. PubMed ID: 21652097
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality in the TRITON trial: update from the FDA prasugrel action package.
    Serebruany VL
    Am J Cardiol; 2010 May; 105(9):1356-7. PubMed ID: 20403493
    [No Abstract]   [Full Text] [Related]  

  • 20. Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.
    Kaul S; Diamond GA
    Arch Intern Med; 2010 Jun; 170(12):1010-2. PubMed ID: 20585063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.